6 minute read
Dec. 18, 2023

JT001: Jecure’s Early, Acquired NLRP3 Inhibitor with an Unexpected Toxicity


NLRP3 inflammasome inhibitor oral efficacy in models; related to Ph. I candidate GDC-2394 from MCC950 and opt. for lipophilic ligand efficacy J. Pharmacol. Exp. Ther., August 1, 2023 Jecure / Genentech, CA


Jecure’s JT001 is a selective inhibitor of NLRP3 inflammasome and among the earlier compounds in this now highly competitive space. In 2018, Genentech bought Jecure Therapeutics for an undisclosed amount, gaining access to Jecure’s NLRP3 inhibitor JT001. While there are many other NLRP3 inhibitors now in the space, JT001 is an interesting example of an initial attempt to overcome liver toxicity with well-known NLRP3 inhibitor MCC950. However, the molecule ran into its own kidney toxicity issues, making this an intriguing toxicology case study.



Other molecules you may be interested in